Ajanta Pharma

{
  "main_header": {
    "sid": 178818,
    "name": "Ajanta Pharma",
    "stock_name": "Ajanta Pharma",
    "full_name": "Ajanta Pharma Ltd.",
    "name_url": "stocks-analysis/ajanta-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,880.10",
    "chg": 94.2,
    "chgp": "3.38%",
    "dir": 1,
    "prev_price": "2,785.90",
    "mcapval": "34,908.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532331,
    "symbol": "AJANTPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE031B01049",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1.26 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ajanta-pharma-178818-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3817055",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AjantaPharmaLtd_technicaldot_3817055.png",
        "date": "2026-02-03 08:00:26",
        "description": "Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum as of early February 2026. While the stock’s overall trend remains mildly bullish, a detailed analysis of key technical indicators such as MACD, RSI, moving averages, and others reveals a complex picture that investors should carefully consider."
      },
      {
        "title": "Ajanta Pharma Ltd. Technical Momentum Shifts Signal Bullish Outlook",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-technical-momentum-shifts-signal-bullish-outlook-3813497",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AjantaPharmaLtd_technicaldot_3813497.png",
        "date": "2026-02-01 08:00:24",
        "description": "Ajanta Pharma Ltd. has witnessed a notable shift in its technical momentum, with key indicators signalling an increasingly bullish trend. Following a recent upgrade from Hold to Buy by MarketsMOJO on 22 Dec 2025, the pharmaceutical company’s stock price has gained 2.81% in the latest session, reflecting renewed investor confidence amid mixed but improving technical signals."
      },
      {
        "title": "Ajanta Pharma Ltd. Reports Strongest Quarterly Performance, Upgrades Financial Trend to Positive",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-reports-strongest-quarterly-performance-upgrades-financial-trend-to-positive-3813457",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AjantaPharmaLtd_fintrenddot_3813457.png",
        "date": "2026-02-01 08:00:10",
        "description": "Ajanta Pharma Ltd. has delivered its highest quarterly financial results to date for the December 2025 quarter, prompting an upgrade in its investment rating from Hold to Buy. The pharmaceutical company’s robust revenue growth, margin expansion, and earnings surge mark a significant positive shift in its financial trajectory, outpacing sector peers and demonstrating resilience amid a challenging macroeconomic backdrop."
      },
      {
        "title": "Are Ajanta Pharma Ltd. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ajanta-pharma-ltd-latest-results-good-or-bad-3811862",
        "imagepath": "",
        "date": "2026-01-30 19:20:09",
        "description": "Ajanta Pharma Ltd. reported its Q3 FY26 results, showcasing a solid performance in terms of revenue and profit growth. The company achieved net sales of ₹1,374.84 crores, reflecting a year-on-year growth of 19.95%, which is a significant improvement compared to the previous year's growth rate of 3.71%. This indicates a strong ability to capture market share, particularly within its branded generics segment across various regions.\n\nThe net profit for the quarter stood at ₹273.77 crores, marking a year-on-year increase of 17.56%, up from 10.88% in the same quarter last year. This growth in profitability, while commendable, is accompanied by a nuanced margin narrative. The operating margin (excluding other income) was reported at 27.80%, which, although an improvement from the previous quarter, reflects a slight contraction compared to the same period last year.\n\nThe company faced challenges with rising employ..."
      },
      {
        "title": "Ajanta Pharma Q3 FY26: Margin Pressures Cloud Revenue Growth Story",
        "link": "https://www.marketsmojo.com/news/result-analysis/ajanta-pharma-q3-fy26-margin-pressures-cloud-revenue-growth-story-3811801",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AjantaPharma_quaterlyResult_3811801.png",
        "date": "2026-01-30 17:45:42",
        "description": "Ajanta Pharma Ltd., a mid-cap specialty pharmaceutical formulation company with a market capitalisation of ₹34,382 crores, reported net profit of ₹273.77 crores for Q3 FY26 (October-December 2025), marking a sequential improvement of 5.22% quarter-on-quarter but a year-on-year growth of 17.56%. The stock surged 2.81% on January 30, 2026, closing at ₹2,770.50, as investors digested the mixed quarterly performance that showcased strong revenue momentum tempered by margin compression concerns."
      },
      {
        "title": "Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-ltd-is-rated-hold-by-marketsmojo-3804163",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AjantaPharmaLtd_mojoScore_3804163.png",
        "date": "2026-01-25 10:10:04",
        "description": "Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3793621",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AjantaPharmaLtd_technicaldot_3793621.png",
        "date": "2026-01-19 08:00:18",
        "description": "Ajanta Pharma Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade from Sell to Hold, the stock’s technical indicators reveal a cautiously optimistic outlook amid broader market volatility."
      },
      {
        "title": "Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-ltd-is-rated-hold-by-marketsmojo-3791954",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AjantaPharmaLtd_mojoScore_3791954.png",
        "date": "2026-01-14 10:10:04",
        "description": "Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 14 January 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing."
      },
      {
        "title": "Ajanta Pharma Declines 5.75%: Technical Momentum and Market Volatility Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-declines-575-technical-momentum-and-market-volatility-shape-the-week-3789003",
        "imagepath": "",
        "date": "2026-01-11 14:00:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>5 Jan:</strong> Formation of Golden Cross signalling potential bullish breakout</p>\n                    <p><strong>7 Jan:</strong> Technical momentum shifts amid mixed monthly indicators</p>\n                    <p><strong>9 Jan:</strong> Week closes at Rs.2,767.65, down 5.75%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,920.85</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.2,767.65</div><div class=\"stat-change negative\">-5.75%</div></div>\n                    <div class=\"stat-..."
      }
    ],
    "total": 608,
    "sid": "178818",
    "stock_news_url": "https://www.marketsmojo.com/news/ajanta-pharma-178818"
  },
  "announcements": [
    {
      "details": "Ajanta Pharma Limited has informed the Exchange regarding Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI ( LODR) , 2015.",
      "source": "NSE",
      "caption": "Ajanta Pharma Limited - Other General Purpose",
      "datetime": "27-Nov-2019"
    },
    {
      "details": "Ajanta Pharma Limited has informed the Exchange regarding Investor Presentation",
      "source": "NSE",
      "caption": "Ajanta Pharma Limited - Investor Presentation",
      "datetime": "06-Nov-2019"
    },
    {
      "details": "Ajanta Pharma Limited has informed the Exchange that the Company has fixed Record Date as November 18, 2019 for the purpose of Interim dividend",
      "source": "NSE",
      "caption": "Ajanta Pharma Limited - Record Date",
      "datetime": "23-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has declared <strong>1400%</strong> dividend, ex-date: 10 Nov 25",
          "dt": "2025-11-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>2:5</strong> stock split, ex-date: 20 Mar 15",
          "dt": "2015-03-20",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>1:2</strong> bonus issue, ex-date: 22 Jun 22",
          "dt": "2022-06-22",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals

2026-02-03 08:00:26

Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum as of early February 2026. While the stock’s overall trend remains mildly bullish, a detailed analysis of key technical indicators such as MACD, RSI, moving averages, and others reveals a complex picture that investors should carefully consider.

Read full news article

Ajanta Pharma Ltd. Technical Momentum Shifts Signal Bullish Outlook

2026-02-01 08:00:24

Ajanta Pharma Ltd. has witnessed a notable shift in its technical momentum, with key indicators signalling an increasingly bullish trend. Following a recent upgrade from Hold to Buy by MarketsMOJO on 22 Dec 2025, the pharmaceutical company’s stock price has gained 2.81% in the latest session, reflecting renewed investor confidence amid mixed but improving technical signals.

Read full news article

Ajanta Pharma Ltd. Reports Strongest Quarterly Performance, Upgrades Financial Trend to Positive

2026-02-01 08:00:10

Ajanta Pharma Ltd. has delivered its highest quarterly financial results to date for the December 2025 quarter, prompting an upgrade in its investment rating from Hold to Buy. The pharmaceutical company’s robust revenue growth, margin expansion, and earnings surge mark a significant positive shift in its financial trajectory, outpacing sector peers and demonstrating resilience amid a challenging macroeconomic backdrop.

Read full news article

Are Ajanta Pharma Ltd. latest results good or bad?

2026-01-30 19:20:09

Ajanta Pharma Ltd. reported its Q3 FY26 results, showcasing a solid performance in terms of revenue and profit growth. The company achieved net sales of ₹1,374.84 crores, reflecting a year-on-year growth of 19.95%, which is a significant improvement compared to the previous year's growth rate of 3.71%. This indicates a strong ability to capture market share, particularly within its branded generics segment across various regions. The net profit for the quarter stood at ₹273.77 crores, marking a year-on-year increase of 17.56%, up from 10.88% in the same quarter last year. This growth in profitability, while commendable, is accompanied by a nuanced margin narrative. The operating margin (excluding other income) was reported at 27.80%, which, although an improvement from the previous quarter, reflects a slight contraction compared to the same period last year. The company faced challenges with rising employ...

Read full news article

Ajanta Pharma Q3 FY26: Margin Pressures Cloud Revenue Growth Story

2026-01-30 17:45:42

Ajanta Pharma Ltd., a mid-cap specialty pharmaceutical formulation company with a market capitalisation of ₹34,382 crores, reported net profit of ₹273.77 crores for Q3 FY26 (October-December 2025), marking a sequential improvement of 5.22% quarter-on-quarter but a year-on-year growth of 17.56%. The stock surged 2.81% on January 30, 2026, closing at ₹2,770.50, as investors digested the mixed quarterly performance that showcased strong revenue momentum tempered by margin compression concerns.

Read full news article

Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO

2026-01-25 10:10:04

Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals

2026-01-19 08:00:18

Ajanta Pharma Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade from Sell to Hold, the stock’s technical indicators reveal a cautiously optimistic outlook amid broader market volatility.

Read full news article

Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO

2026-01-14 10:10:04

Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 14 January 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing.

Read full news article

Ajanta Pharma Declines 5.75%: Technical Momentum and Market Volatility Shape the Week

2026-01-11 14:00:06

Key Events This Week

5 Jan: Formation of Golden Cross signalling potential bullish breakout

7 Jan: Technical momentum shifts amid mixed monthly indicators

9 Jan: Week closes at Rs.2,767.65, down 5.75%

Week Open

Rs.2,920.85

Week Close

Rs.2,767.65

-5.75%

Read full news article

View All News